Zobrazeno 1 - 10
of 400
pro vyhledávání: '"Kentaro ITO"'
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract As a member of 2D family, amorphous 2D nanosheets have received increasing attention due to their unique properties that are distinct from crystalline 2D nanosheets. However, compared with the vast library of crystalline 2D nanosheets, amorp
Externí odkaz:
https://doaj.org/article/180006979dd44ba5b29ac817a95a46cf
Autor:
Atsushi Ito, Shu Kano, Tomohito Tarukawa, Yuta Suzuki, Tadashi Sakaguchi, Kentaro Ito, Yoichi Nishii, Osamu Taguchi, Hiroki Yasui, Motoshi Takao, Osamu Hataji
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectivesThis study aimed to assess the intrinsic impacts of the expression of PD-L1 on postoperative recurrence and the prognosis in patients with epidermal growth factor receptor (EGFR)-mutated lung adenocarcinomas.Patients and methodsData from 22
Externí odkaz:
https://doaj.org/article/c0e0b61e81f84ee6a9005026c1576afa
Autor:
Keita Miura, Ou Yamaguchi, Keita Mori, Atsushi Nakamura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Ramucirumab plus docetaxel (RD) can cause febrile neutropenia (FN), which frequently requires the prophylactic administration of pegfilgrastim. However, the effects of prophylactic pegfilgrastim on FN prevention, therapeutic efficacy, and pr
Externí odkaz:
https://doaj.org/article/2b814dbbea994c51a018f1a190fff4f2
Autor:
Kei Nomura, Tomoyoshi Shibuya, Rina Odakura, Mayuko Haraikawa, Hirotaka Ishino, Masayuki Orikasa, Masashi Omori, Masao Koma, Kentaro Ito, Takafumi Maruyama, Osamu Nomura, Dai Ishikawa, Mariko Hojo, Akihito Nagahara
Publikováno v:
Biomedicines, Vol 12, Iss 9, p 1991 (2024)
Ulcerative colitis (UC) is a chronic inflammatory disorder of the large intestine. Data on the comparative effectiveness of biological therapies such as vedolizumab (VDZ) and ustekinumab (UST) remain limited. This retrospective study compared the eff
Externí odkaz:
https://doaj.org/article/25a4d36426214053881dfc1299f9c8c5
Autor:
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Kentaro Ito, Atsushi Fujiwara, Hisamichi Yuda, Hidetoshi Itani, Masahiro Naito, Shuji Kodama, Kazuki Furuhashi, Akihiko Yagi, Haruko Saiki, Taro Yasuma, Tomohito Okano, Atsushi Tomaru, Motoaki Tanigawa, Masamichi Yoshida, Osamu Hataji, Hidenori Ibata, Corina N. D'Alessandro‐Gabazza, Esteban C. Gabazza, Tetsu Kobayashi
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Background Immune checkpoint inhibitors have recently become the standard of care in the first‐line treatment of extensive‐stage small cell lung cancer. Although immune‐related adverse events have been reported to influence prognosis i
Externí odkaz:
https://doaj.org/article/9d71cbd6a1434c5a9a3174265afbb05d
Autor:
Yoichi Nishii, Tadashi Sakaguchi, Seiya Esumi, Maki Esumi, Yuki Nakamura, Yuta Suzuki, Kentaro Ito, Kentaro Fujiwara, Hiroki Yasui, Atsushi Ito, Tomohito Tarukawa, Tatsuki Tsuruga, Corina N. D’Alessandro-Gabazza, Taro Yasuma, Hajime Fujimoto, Fumihiro Asano, Esteban C. Gabazza, Tetsu Kobayashi, Osamu Taguchi, Osamu Hataji
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Bronchoscopy with radial-probe endobronchial ultrasound, a guide sheath, and electromagnetic navigation can improve the diagnostic yield of peripheral lung nodules. However, the suitability of specimens for genetic analysis remains unsatisfa
Externí odkaz:
https://doaj.org/article/a2c13dc2ba6649e2a9221fce980caed2
Autor:
Kentaro Ito, Miho Nishio, Kentaro Fujiwara, Yoichi Nishii, Kengo Ushiro, Hiroki Yasui, Osamu Hataji
Publikováno v:
Thoracic Cancer, Vol 14, Iss 25, Pp 2622-2626 (2023)
Abstract Entrectinib, a ROS‐1 inhibitor, has been shown to be effective for patients with ROS‐1 fused NSCLC, and has been established as the standard of care for this population. Entrectinib has been shown to achieve a better response to brain me
Externí odkaz:
https://doaj.org/article/c9e35c4ba19f4a5ab1b76c5ed0c10dfb
Autor:
Tadashi Sakaguchi, Akemi Iketani, Seiya Esumi, Maki Esumi, Yuta Suzuki, Kentaro Ito, Kentaro Fujiwara, Yoichi Nishii, Koji Katsuta, Hiroki Yasui, Osamu Taguchi, Osamu Hataji
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Although we have experienced some cases with discordant results between the Oncomine Dx target test (ODxTT) and conventional single gene tests for detecting EGFR alterations, the clinical efficacy of EGFR-TKIs in these discordant cases remai
Externí odkaz:
https://doaj.org/article/ddd62a66fcb44038aa5b340a85e0848e
Autor:
Daisuke Hazama, MD, PhD, Kenji Nakahama, MD, PhD, Hiroaki Kodama, MD, Akito Miyazaki, MD, Koichi Azuma, MD, PhD, Yosuke Kawashima, MD, Yuki Sato, MD, Kentaro Ito, MD, Yoshimasa Shiraishi, MD, Keita Miura, MD, Takayuki Takahama, MD, PhD, Satoshi Oizumi, MD, PhD, Yoshinobu Namba, MD, Satoshi Ikeda, MD, PhD, Hiroshige Yoshioka, MD, PhD, Asuka Tsuya, MD, PhD, Yuichiro Yasuda, MD, PhD, Yoshiki Negi, MD, PhD, Ayako Hara, MD, Michihito Toda, MD, PhD, Motoko Tachihara, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 1, Pp 100613- (2024)
Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were foun
Externí odkaz:
https://doaj.org/article/ceb8623f26cd4608b0d8ffd019ba6537
Autor:
Reiko Matsuzawa, Masahiro Morise, Kentaro Ito, Osamu Hataji, Kosuke Takahashi, Junji Koyama, Yachiyo Kuwatsuka, Yasuhiro Goto, Kazuyoshi Imaizumi, Hidetoshi Itani, Teppei Yamaguchi, Yoshitaka Zenke, Masahide Oki, Makoto Ishii
Publikováno v:
EClinicalMedicine, Vol 66, Iss , Pp 102303- (2023)
Summary: Background: Immune checkpoint inhibitors (ICI) plus platinum-based chemotherapy has been recognized as a standard first-line therapy in non-small cell lung cancer (NSCLC); however, no prospective clinical trials of docetaxel (DTX) plus ramuc
Externí odkaz:
https://doaj.org/article/5bf2a2ed2cfa401eb7d3e4461978588a